Purpose: Kidney stones are a common and painful condition. Longitudinal prospective studies on the association between the intake of vitamin D and the risk of incident kidney stones are lacking.
which in turn might be increased by higher circulating levels of 1,25-dihydroxyvitamin D. 3, 4 In a prospective, nested, case-control study the odds of kidney stones were 73% higher for those in the highest quartile of 1, 25 [OH] 2 D. 5 The association between precursors of 1, 25 [OH] 2 D such as circulating 25-hydroxyvitamin D and intake of cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) is less clear. Oral supplementation with cholecalciferol has been associated with an increased risk of stones when administered together with calcium. 6 However, administration of ergocalciferol in stone formers with vitamin D deficiency did not cause a significant increase in mean urinary No direct or indirect commercial incentive associated with publishing this article.
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15e18 To date only 2 longitudinal studies to our knowledge have investigated the association between vitamin D intake and kidney stone risk, reporting no association. 19, 20 We designed the current study to investigate total and supplemental intake of vitamin D and the risk of incident kidney stones in the large prospective cohorts of the HPFS and the NHS I and II.
MATERIALS AND METHODS

Study Cohorts
The HPFS cohort was started in 1986 with the enrollment of 51,529 male health professionals (dentists, optometrists, osteopaths, pharmacists, podiatrists and veterinarians) age 40 to 75 years. The NHS I cohort was started in 1976 with the enrollment of 121,700 female nurses age 30 to 55 years and the NHS II cohort was started in 1989 with the enrollment of 116,430 female nurses age 25 to 42. For all the cohorts the participants completed a detailed questionnaire with information on lifestyle, medical history and medications. The questionnaire was subsequently mailed every 2 years to update information. These studies were approved by the Partners HealthCare institutional review board. Return of completed baseline and biennial questionnaires was accepted by the institutional review board as implied informed consent.
Assessment of Vitamin D and Other Nutrient Intake
Starting in 1986 (for HPFS and NHS I) and 1991 (for NHS II) participants submitted a FFQ with information on average use of more than 130 foods and more than 20 beverages in the previous year. Intake of individual nutrients was calculated from the frequency of consumption of foods and from data on the content of the relevant nutrients obtained from the U.S. Department of Agriculture, except for oxalate intake, which was directly measured in foods by capillary electrophoresis. 21 Participants reported intake of vitamin D supplements. Participants reporting intake of a multivitamin were asked to report the specific brand and the amount and frequency of use. This information was used to calculate supplemental vitamin D intake using a composition database on more than 1,000 multivitamin brands. Intakes estimated from the FFQ were validated in the NHS I and HPFS cohorts. Intraclass correlation coefficients for total vitamin and mineral intakes assessed by 2 FFQs 1 year apart ranged from 0.58 to 0.60 in the NHS I and from 0.57 to 0.80 in the HPFS.
22,23
Assessment of Kidney Stones and Other Covariates
Participants reporting an incident kidney stone were asked to complete a supplementary questionnaire with information about date of occurrence and accompanying symptoms. Self-reported diagnosis was reliable by medical record review of a sample (confirmed in 95% or more who completed the supplementary questionnaire). 24 In a subsample of the study population with stone composition reports stone type was predominantly calcium oxalate (greater than 50%) in 86% of participants in the HPFS, 77% of participants in the NHS I and 79% of participants in the NHS II cohort. 24 Information about age, region of living, BMI, history of diabetes, history of hypertension and use of thiazides was obtained from the biennial questionnaire.
Statistical Analysis
Participants were divided into categories according to total vitamin D intake (less than 100, 100 to 199, 200 to 399, 400 to 599, 600 to 999, 1,000 or greater IU per day) and supplemental vitamin D intake (none, less than 400, 400 to 599, 600 to 999, 1,000 or greater IU per day). Person-time of followup was allocated to each category from the start of followup (1986 for HPFS and NHS I, 1991 for NHS II) until the date of incident stones, death or end of followup (2012 for HPFS and NHS I, 2011 for NHS II), whichever happened first. Participants were excluded from analysis at baseline if they reported a history of kidney stones or malignancy (except for nonmelanoma skin cancer), and were censored during followup if they reported an incident malignancy. Cox proportional hazards regression models were used to calculate hazard ratios and 95% CIs for incident stones for each category of exposure. Models were adjusted for age, region of residence, BMI, history of diabetes, history of hypertension, use of thiazides, use of calcium supplements, and intake of calcium, sodium, potassium, magnesium, animal protein, fructose, oxalate, vitamin C, caffeine, alcohol and fluids. Models for supplemental vitamin D intake were further adjusted for dietary vitamin D. Exposures and covariates were updated every 4 years.
Effect modification of total vitamin D intake by age (less than 50 vs 50 years or greater) or BMI (less than 25 vs 25 kg/m 2 or greater) was tested by including interaction terms in the multivariate adjusted models. Effect modification of total vitamin D intake by total calcium intake was tested by interaction terms of the intakes expressed as continuous variables and by generating HRs for joint categories of exposure (total vitamin D less than 400, 400 to 799, 800 IU per day or greater; total calcium intake less than 600, 600 to 1,199, 1,200 mg per day or greater).
RESULTS
Our analysis included 193,551 participants, whose baseline characteristics are reported in table 1. Average age (except for NHS II), use of calcium supplements, and intake of potassium, magnesium, animal protein and vitamin C tended to increase with increasing categories of total vitamin D intake, whereas intake of caffeine (except for NHS II) and alcohol tended to decrease. During a followup of 3,316,846 person-years there were 6,576 incident kidney stone events.
Estimates of association between total vitamin D intake and kidney stones are reported in table 2. After multivariate adjustment there was no statistically significant association in the HPFS cohort (HR for a daily intake of 1,000 IU or more vs less than 100 IU 1.08; 95% CI 0.80, 1.47; p for trend ¼ 0.92) and in the NHS I cohort (HR 0.99; 95% CI 0.73, 1.35; p for trend ¼ 0.70). In the NHS II cohort there was a suggestion that the highest category of vitamin D intake was associated with a higher risk of stones (HR 1.18; 95% CI 0.94, 1.48; p for trend ¼ 0.02).
Estimates of association between supplemental vitamin D intake and kidney stones are reported in table 3. Similar to total intake, there was no significant association after multivariate adjustment in the HPFS (HR for the highest vs lowest category 1.23; 95% CI 0.81, 1.86; p for trend ¼ 0.34) and the NHS I (HR for the highest vs lowest category 1.03; 95% CI 0.71, 1.51; p for trend ¼ 0.26), whereas the association was significant in the NHS II (HR for the highest vs lowest category 1.38; 95% CI 1.03, 1.85; p for trend ¼ 0.02). When we examined the cumulative average of total vitamin D intake we found no association with incident kidney stones in any cohort. There was no effect modification of total vitamin D intake by age, BMI or total calcium intake. 
DISCUSSION
Vitamin D intake was not significantly associated with risk of incident kidney stones in 2 of the cohorts, whereas there was a suggestion of higher risk in the third cohort. Similar results were obtained when analyzing intake of vitamin D from supplements. The potential relevance of vitamin D in the pathogenesis of kidney stones stems from the reported association between higher levels of 1,25(OH) 2 D with urinary calcium excretion (a major determinant of calcium stone formation) 2,4 and with actual stone formation. 5 Since the relationship between vitamin D intake and circulating levels of 25(OH)D, the substrate for 1,25(OH) 2 D, is well established, 25 one might expect that vitamin D intake might increase risk of stones, but the formation of 1,25(OH) 2 D (the active metabolite responsible for intestinal calcium absorption and increased urinary calcium excretion) from 25(OH)D is tightly regulated by down-regulation of the 1-alpha-hydroxylase enzyme or a reduction in parathyroid hormone. In fact, previous studies on the association between vitamin D intake and the risk of kidney stones do not support this hypothesis. Supplemental administration of vitamin D3 to attain circulating levels of 25(OH)D greater than 32 ng/ml in a group of 138 participants did not significantly increase mean urinary excretion of calcium. 26 Similarly, daily administration of up to 4,000 IU vitamin D3 in a group of 73 healthy volunteers did not modify urine calcium substantially. 27 Leaf et al treated 29 calcium stone formers with 25(OH)D levels less than 30 ng/ml and urine calcium excretion between 150 and 400 mg/24 hours with vitamin D2 (50,000 IU per week for 8 weeks), and reported that mean urine calcium excretion did not increase overall (from 257AE54 to 255AE88 mg/24 hours), although in 11 patients there was an increase in urine calcium of 20 mg/24 hours or greater. 7 In this setting it is possible that altered function of 24-hydroxylase, the enzyme degrading 1,25(OH) 2 D, might have a role in the differential calciuric response to vitamin D. 28 Previous analyses of the HPFS cohort did not find any association between either total vitamin D intake 19 or circulating levels 5 of 25(OH)D and risk of stones. Similarly, among 2,012 participants of the GrassrootsHealth study no association was observed between intake of vitamin D3 and the incidence of stones. 20 However, the results were limited by the small number of stone events (13 cases) and the short followup time (1.6 years). 20 In the only study to our knowledge reporting an increased risk of kidney stones after the administration of vitamin D, supplemental vitamin D was given together with calcium supplements, which might have increased urine calcium excretion. 6 However, in our study we did not observe a higher risk even among those participants with higher calcium intake.
We found a statistically significant linear trend for a higher risk of stones in the NHS II cohort, but visual inspection of the individual HRs in the vitamin D categories does not support a monotonic increase in risk. It appears that the risk of stones was only higher in the highest category of intake, suggesting a nonlinear association in this cohort.
Our study has limitations, including the observational study design and that the majority of the participants were white. We also did not have access to information on stone and urine composition for the majority of the participants. We could not fully explore the association between vitamin D intake and stones across all age ranges of men, but in the NHS II cohort we could analyze 422 incident cases that occurred during 186,286 person-years of followup. While it is possible that the association of vitamin D intake with stone risk might vary between younger and older adults, we did not find significant effect modification by age in the participants of the NHS II cohort. We lacked information from the participants about the indication for vitamin D supplementation. Finally, few individuals had a vitamin D intake greater than 1,000 IU per day. Taken together, our findings suggest that vitamin D intake in typical amounts was not statistically associated with risk of kidney stone formation. However, higher risk with higher doses cannot be excluded.
provides important insights. Analyzing data from 3 large cohorts, vitamin D supplements did not associate with incident stones, except in the younger female cohort at doses greater than 1,000 IU per day. Of note, very few in the other cohorts ingested this amount of vitamin D. This study provides reassurance that vitamin D intake less than 1,000 IU per day, either dietary or supplemental, probably does not increase stone risk in the general population. The question of whether genetics might impact associations of vitamin D intake and stone risk, in particular in relation to CYP24A1 polymorphisms, was not addressed.
